Modified active gas sampling

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
FDA, Tremor, Part, CNS, GLOBE, Investment, Therapeutic index, ET, Modified active gas sampling, Patient, ADL, Central nervous system, Safety, Epilepsy, NASDAQ, Â, Genetics, Essential tremor, Pharmaceutical industry, Praxis

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022.

Key Points: 
  • The Company expects topline results from the ongoing PRAX-944 Essential1 Study in the fourth quarter of 2022.
  • In June 2022, following the PRAX-114 Aria Study results, the Company discontinued the PRAX-114 Phase 2 study for the treatment of ET.
  • Second Quarter 2022 Financial Results:
    As of June 30, 2022, Praxis had $165.4 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash, cash equivalents and marketable securities as of December 31, 2021.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
Part, Investment, Post-traumatic stress disorder, NASDAQ, Modified active gas sampling, GLOBE, CNS, Company, Major depressive disorder, Food, Safety, Essential tremor, Patient, Tremor, ADL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PTSD, MDD, Central nervous system, Medical device, Pharmaceutical industry, Praxis

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the first quarter 2022.

Key Points: 
  • The Company anticipates topline results from the PRAX-114 Phase 2, placebo-controlled, dose-ranging Acapella Study for treatment of MDD in the third quarter of 2022.
  • Praxis reported positive topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944 for the treatment of essential tremor (ET).
  • Praxis will host a Q&A session focused on todays corporate update and financial results for the first quarter 2022 via a conference call and webcast today, May 9, 2022, at 4:30 p.m.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

Retrieved on: 
Monday, May 9, 2022
Part, GLOBE, Safety, Essential tremor, Central nervous system, Patient, Tremor, ADL, NASDAQ, Modified active gas sampling, CNS, Medical device, Pharmaceutical industry

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944 for the treatment of essential tremor (ET). In the study, treatment with PRAX-944 resulted in clinically meaningful improvements in function, which were supported by improvements in tremor amplitude.

Key Points: 
  • In the study, treatment with PRAX-944 resulted in clinically meaningful improvements in function, which were supported by improvements in tremor amplitude.
  • The data from the PRAX-944 Phase 2a study offer hope to people living with essential tremor, for a treatment developed specifically for ET, said Bernard Ravina, M.D., chief medical officer of Praxis.
  • Part B of the Phase 2a study of PRAX-944 for the treatment of ET included both an open-label and randomized withdrawal period.
  • PRAX-944 was generally well tolerated in Part B of the Phase 2a study, with no new safety findings.